Bisphosphonate-prostatic Acid Phosphatase Inhibitor Conjugates to Treat Prostate Cancer Bone Metastasis
The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is alendronate, and it is covalently bonded to either tartaric acid or glyceric acid.
Patents:WO 2,011,035,031
Inventor(s):
KIRSCHENBAUM ALEXANDER [US]; LEVINE ALICE C [US]; REGEN STEVEN L [US]; JANOUT VACLAV [US]
Type of Offer:
Licensing
« More Biotech Patents